Company profile for Aeglea BioTherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Aeglea was founded in 2013 to reimagine the potential of human enzyme therapeutics. Our relentless mission is to deliver disruptive solutions that can provide meaningful benefit for many patients with rare genetic diseases. Every day, we work to… Look beyond the conventional, redefining the potential of human enzymes to deliver disruptive solutions Work with purpose, driven by the urgent needs of the communities we serv...
Aeglea was founded in 2013 to reimagine the potential of human enzyme therapeutics. Our relentless mission is to deliver disruptive solutions that can provide meaningful benefit for many patients with rare genetic diseases. Every day, we work to… Look beyond the conventional, redefining the potential of human enzymes to deliver disruptive solutions Work with purpose, driven by the urgent needs of the communities we serve Pursue our vision to become the premier human enzyme company And ultimately, change the lives of patients and their families now and for the future

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
805 Las Cimas Parkway, Suite 100, Austin, TX 78746
Telephone
Telephone
(512) 942-2935
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://endpts.com/aeglea-rebrands-to-spyre-names-new-ceo-in-ibd-race-against-tl1a-drugs-at-merck-roche-and-sanofi/

Kyle LaHucik ENDPTS
27 Nov 2023

https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-name-change-to-spyre-therapeutics-appoints-ceo-and-additional-directors-and-expands-leadership-team-to-develop-next-generation-therapeutic-combinations-for-the-treatment-of-ibd-301996712.html

PR NEWSWIRE
27 Nov 2023

https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-sale-of-pegzilarginase-to-immedica-pharma-301887231.html

PR NEWSWIRE
27 Jul 2023
Aeglea sells off rare disease asset to Immedica for $15M
Aeglea sells off rare disease asset to Immedica for $15M

27 Jul 2023

// Gabrielle Masson FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/immedica-takes-embattled-rare-disease-asset-aegleas-hands-15m-cash

Gabrielle Masson FIERCE BIOTECH
27 Jul 2023

https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-acquisition-of-spyre-therapeutics-301858013.html

PR NEWSWIRE
22 Jun 2023

https://www.biopharmadive.com/news/spyre-aeglea-reverse-merger-paragon-tl1a-ibd/653672/

BIOPHARMADIVE
21 Jun 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty